A Multiple Oral Doses Study Of PF-06427878 In Healthy Adult Subjects

Phase 1 Completed 40 enrolled Pfizer

RandomizedTriple-blindBasic science

Summary

PF-06427878 is a new compound proposed for the treatment of hyperlipidemia. The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple oral doses of PF-06427878 in healthy adult subjects.

Timeline

Start: 2015-03
Primary completion: 2016-02
Completion: 2016-02

Publications

Amin NB, Carvajal-Gonzalez S, Purkal J, Zhu T, Crowley C, Perez S, Chidsey K, Kim AM, Goodwin B. Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis. Sci Transl Med. 2019 Nov 27;11(520):eaav9701. doi: 10.1126/scitranslmed.aav9701.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PF-06427878	Small molecule	5 mg	Oral
Subject	PF-06427878	Small molecule	1500 mg	Oral

Indications

No indication recorded.